SEC For	m 4																			
	FORM	4	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549														OMB	APPRO		
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).				STATEMENT OF CHANGES IN BENEFICIAL OWNE Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940									-	SHIP	Estin	OMB Number: 3235-0287 Estimated average burden hours per response: 0.5				
1. Name and Address of Reporting Person [*] Guyer William						2. Issuer Name and Ticker or Trading Symbol <u>CORCEPT THERAPEUTICS INC</u> [CORT]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (specify				wner	
	(Last) (First) (Middle) C/O CORCEPT THERAPEUTICS INCORPORATED 149 COMMONWEALTH DRIVE					3. Date of Earliest Transaction (Month/Day/Year) 02/13/2022									A below) below) Chief Development Officer					
(Street) MENLO PARK CA 94025				4. l	4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City) (State) (Zip)						ative Securities Acquired, Disposed of, or Benefic														
Iable I - Non-Deriv 1. Title of Security (Instr. 3) 2. Transa Date (Month/E)				actior	n	2A. Deemed Execution Date, if any (Month/Day/Yea		, 3. Transaction Code (Instr.		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4		d (A) or	r 5. Amount of		Form	nership : Direct · Indirect str. 4)	7. Nature of Indirect Beneficial Ownership			
									Code	v	Amou	Amount (A) or (D)		Price	Transaction(s) (Instr. 3 and 4)				(Instr. 4)	
			Table II -				urities Is, warr								Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution D if any (Month/Day/	ate, Tr Co	ansac ode (Ir		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Ex Expiration (Month/Da	e	of Securities		es Security	8. Price of Derivative Security (Instr. 5)	9. Numb derivativ Securitie Benefici Owned Followin Reporte	ve es ally Ig d	10. Ownershij Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership t (Instr. 4)		
				Ca	ode	v					Expiratio Date		Amo or Num Title of Sh			Transac (Instr. 4)				

(1)

Explanation of Responses:

\$23.06

1. Exercisable ratably in equal installments on each monthly anniversary of February 13, 2023 over a four-year period.

Remarks:

Stock option (right to buy)

The power of attorney under which this form was signed is on file with the Commission.

02/13/2023

/s/ Joseph Douglas Lyon, as attorney-in-fact for William

200,000

\$0.00

Common

Stock

02/12/2033

02/15/2023

200,000

D

Guyer ** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Α

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

200,000